Detalhe da pesquisa
1.
TP53 gene mutations as an independent marker for urinary bladder cancer progression.
Int J Mol Med
; 21(5): 655-61, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18425359
2.
Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells.
Cancer Gene Ther
; 11(7): 477-86, 2004 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15118762
3.
TP53 gene mutations in prostate cancer progression.
Anticancer Res
; 30(5): 1579-86, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20592345
4.
Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
Mol Ther
; 14(6): 768-78, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16990052
5.
Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
J Pharmacol Exp Ther
; 319(2): 533-42, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16868035
6.
Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.
J Urol
; 174(6): 2129-33, discussion 2133, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16280742
7.
Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer.
Urology
; 60(3): 531-6, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12350512